Survival Benefit in Metastatic CRPC Study Spurs Questions on Patient Selection

[ad_1]

(MedPage Today) — In a recent MedPage Today video, Neeraj Agarwal, MD, of the Huntsman Cancer Institute at the University of Utah in Salt Lake City, reviewed the TALAPRO-2 trial’s implications for frontline treatment of metastatic castration-resistant…

[ad_2]

Source link : https://www.medpagetoday.com/meetingcoverage/gucsfuturefocus/114790

Author :

Publish date : 2025-03-24 15:24:00

Copyright for syndicated content belongs to the linked Source.